Pfizer 2009 Annual Report Download - page 103

Download and view the complete annual report

Please find page 103 of the 2009 Pfizer annual report below. You can navigate through the pages in the report by either clicking on the pages listed below, or by using the keyword search tool below to find specific information within the annual report.

Page out of 110

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • 34
  • 35
  • 36
  • 37
  • 38
  • 39
  • 40
  • 41
  • 42
  • 43
  • 44
  • 45
  • 46
  • 47
  • 48
  • 49
  • 50
  • 51
  • 52
  • 53
  • 54
  • 55
  • 56
  • 57
  • 58
  • 59
  • 60
  • 61
  • 62
  • 63
  • 64
  • 65
  • 66
  • 67
  • 68
  • 69
  • 70
  • 71
  • 72
  • 73
  • 74
  • 75
  • 76
  • 77
  • 78
  • 79
  • 80
  • 81
  • 82
  • 83
  • 84
  • 85
  • 86
  • 87
  • 88
  • 89
  • 90
  • 91
  • 92
  • 93
  • 94
  • 95
  • 96
  • 97
  • 98
  • 99
  • 100
  • 101
  • 102
  • 103
  • 104
  • 105
  • 106
  • 107
  • 108
  • 109
  • 110

Notes to Consolidated Financial Statements
Pfizer Inc. and Subsidiary Companies
Revenues by Product
Significant product revenues are as follows:
YEAR ENDED DECEMBER 31,
(MILLIONS OF DOLLARS) 2009 2008 2007
Biopharmaceutical products:
Lipitor $11,434 $12,401 $12,675
Lyrica 2,840 2,573 1,829
Celebrex 2,383 2,489 2,290
Norvasc 1,973 2,244 3,001
Viagra 1,892 1,934 1,764
Xalatan/Xalacom 1,737 1,745 1,604
Detrol/Detrol LA 1,154 1,214 1,190
Zyvox 1,141 1,115 944
Geodon/Zeldox 1,002 1,007 854
Sutent 964 847 581
Genotropin 887 898 843
Vfend 798 743 632
Chantix/Champix 700 846 883
Caduet 548 589 568
Effexor(a) 520 ——
Zoloft 516 539 531
Aromasin 483 465 401
Cardura 457 499 506
Revatio 450 336 201
Aricept(b) 432 482 401
Zithromax/Zmax 430 429 438
Enbrel(a), (c) 378 ——
Prevnar/Prevenar 7(a) 287 ——
Premarin family(a) 213 — —
Zosyn/Tazocin(a) 184 ——
BeneFIX(a) 98 ——
ReFacto/Xyntha(a) 47 ——
All Other(d) 8,575 8,528 10,499
Alliance revenues (Enbrel (in the U.S. and Canada)(a), Aricept, Exforge, Rebif and Spiriva) 2,925 2,251 1,789
Total Biopharmaceutical products 45,448 44,174 44,424
Diversified products:
Animal health products(d) 2,764 2,825 2,639
Consumer healthcare products(a) 494 ——
Capsugel(e) 740 767 685
Nutrition products(a) 191 ——
Total Diversified products 4,189 3,592 3,324
Corporate/Other 372 530 670
Total revenues $50,009 $48,296 $48,418
(a) Legacy Wyeth products and operations. In accordance with Pfizer’s domestic and international year-ends, includes approximately
two-and-a-half months of Wyeth’s U.S. operations and approximately one-and-a-half months of Wyeth’s international operations in
2009.
(b) Represents direct sales under license agreement with Eisai.
(c) Outside the U.S. and Canada.
(d) Includes legacy Pfizer and legacy Wyeth products in 2009.
(e) Prior-period amounts for Capsugel, which were previously classified in Corporate/Other are now classified in Diversified.
2009 Financial Report 101